Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice

International Journal of Neuropsychopharmacology

Volumn 13, Issue 6, 2010, Pages 759-774

  Païzanis, Eleni ^a,b   Renoir, Thibault ^a,b   Lelievre, Vincent ^a   Saurini, Françoise ^a,b   Melfort, Maxette ^a,b   Gabriel, Cecilia ^c   Barden, Nicholas ^d   Mocaër, Elisabeth ^c   Hamon, Michel ^a,b   Lanfumey, Laurence ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c IRIS Institut de Recherches Internationales Servier   (France)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

BDNF; hippocampus; hypothalamic pituitary adrenocortical axis; neurogenesis; transgenic mice

Indexed keywords

AGOMELATINE; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; BROXURIDINE; DOUBLECORTIN PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NEUROPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILIZATION; MALE; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; CELL DEATH; CYTOLOGY; DEFICIENCY; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NICK END LABELING; PHYSIOLOGY; PROCEDURES; RAT; TRANSGENIC MOUSE;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; BROMODEOXYURIDINE; CELL DEATH; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HINDLIMB SUSPENSION; HIPPOCAMPUS; IN SITU NICK-END LABELING; MALE; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NEURONAL PLASTICITY; NEUROPEPTIDES; RATS; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER;

EID: 77957144923     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990514     Document Type: Article

References (66)

1. Alfonso J, Frick LR, Silberman DM, Palumbo ML, et al. (2006). Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biological Psychiatry 59, 244-251.
2. Alonso R, Griebel G, Pavone G, Stemmelin J, et al. (2004). Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Molecular Psychiatry 9, 278-286. (Pubitemid 38496719)
3. Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, et al. (2003). New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Archives of Pharmacology 367, 553-561.
4. Bai F, Li X, Clay M, Lindstrom T, Skolnick P (2001). Intraand interstrain differences in models of behavioral despair. Pharmacology, Biochemistry and Behavior 70, 187-192.
5. Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A (2006). Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biological Psychiatry 59, 1087-1096.
6. Bannerman DM, Rawlins JN, McHugh SB, Deacon RM, et al. (2004). Regional dissociations within the hippocampus - memory and anxiety. Neuroscience and Biobehavioral Reviews 28, 273-283.
7. Barden N (1996). Modulation of glucocorticoid receptor gene expression by antidepressant drugs. Pharmacopsychiatry 29, 12-22.
8. Barden N, Shink E, Labbe M, Vacher R, et al. (2005). Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 908-916.
9. Barden N, Stec IS, Montkowski A, Holsboer F, Reul JM (1997). Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 66, 212-220.
10. Bauer S, Rasika S, Han J, Mauduit C, et al. (2003). Leukemia inhibitory factor is a key signal for injury-induced neurogenesis in the adult mouse olfactory epithelium. Journal of Neuroscience 23, 1792-1803.
11. Bjartmar L, Johansson IM, Marcusson J, Ross SB, et al. (2000). Selective effects on NGFI-A, MR, GR and NGFI-B hippocampal mRNA expression after chronic treatment with different subclasses of antidepressants in the rat. Psychopharmacology (Berlin) 151, 7-12.
12. Borsini F, Meli A (1988). Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berlin) 94, 147-160.
13. Bourin M, Mocaer E, Porsolt R (2004). Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. Journal of Psychiatry and Neuroscience 29, 126-133.
14. Castren E, Voikar V, Rantamaki T (2007). Role of neurotrophic factors in depression. Current Opinion in Pharmacology 7, 18-21.
15. Chen H, Pandey GN, Dwivedi Y (2006). Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 17, 863-867.
16. Cryan JF, Lucki I (2000). Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. Journal of Pharmacology and Experimental Therapeutics 295, 1120-1126.
17. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and Biobehavioral Reviews 29, 571-625.
18. Czeh B, Lucassen PJ (2007). What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated? European Archives of Psychiatry and Clinical Neuroscience 257, 250-260.
19. Dorio D, Viau V, Meaney MJ (1993). The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. Journal of Neuroscience 13, 3839-3847.
20. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry 59, 1116-1127.
21. Feldman S, Weidenfeld J (1999). Glucocorticoid receptor antagonists in the hippocampus modify the negative feedback following neural stimuli. Brain Research 821, 33-37.
22. Franklin KB, Paxinos G (1997). The Mouse Brain in Stereotaxic Coordinates. Toronto, San Diego: Academic Press.
23. Froger N, Palazzo E, Boni C, Hanoun N, et al. (2004). Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. Journal of Neuroscience 24, 2787-2796.
24. Fuchs E, Flugge G (1998). Stress, glucocorticoids and structural plasticity of the hippocampus. Neuroscience and Biobehavioral Reviews 23, 295-300.
25. Hashimoto K, Shimizu E, Iyo M (2004). Critical role of brain-derived neurotrophic factor in mood disorders. Brain Reserach Reviews 45, 104-114.
26. Holick KA, Lee DC, Hen R, Dulawa SC (2008). Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 33, 406-417.
27. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocrine Reviews 17, 187-205.
28. Husson I, Rangon CM, Lelievre V, Bemelmans AP, et al. (2005). BDNF-induced white matter neuroprotection and stage-dependent neuronal survival following a neonatal excitotoxic challenge. Cerebral Cortex 15, 250-261.
29. Karanth S, Linthorst AC, Stalla GK, Barden N, et al. (1997). Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology 138, 3476-3485. (Pubitemid 27345703)
30. Karege F, Perret G, Bondolfi G, Schwald M, et al. (2002). Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Research 109, 143-148.
31. Keilhoff G, Becker A, Grecksch G, Bernstein HG, Wolf G (2006). Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 31, 1165-1176.
32. Kempermann G, Kronenberg G (2003). Depressed new neurons - adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biological Psychiatry 54, 499-503.
33. Klempin F, Kempermann G (2007). Adult hippocampal neurogenesis and aging. European Archives of Psychiatry and Clinical Neuroscience 257, 271-280.
34. Kodama M, Fujioka T, Duman RS (2004). Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biological Psychiatry 56, 570-580.
35. Lee J, Duan W, Mattson MP (2002). Evidence that brainderived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. Journal of Neurochemistry 82, 1367-1375.
36. Linthorst ACE, Flachskamm C, Barden N, Holsboer F, Reul JM (2000). Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: an in vivo microdialysis study in transgenic mice. European Journal of Neuroscience 12, 283-291.
37. Lucki I (2001). A prescription to resist proscriptions for murine models of depression. Psychopharmacology 153, 395-398.
38. Maccari S, Morley-Fletcher S, Mairesse J, Viltart O, et al. (2005). Chronic treatment with agomelatine reversed the decrease in hippocampal cells neurogenesis and survival in prenatally stressed adults rats. Program No. 566.8. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience 2005. Online.
39. Malberg JE, Duman RS (2003). Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28, 1562-1571.
40. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience 20, 9104-9110.
41. Mayer JL, Klumpers L, Maslam S, de Kloet ER, et al. (2006). Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone-induced reduction of adult hippocampal neurogenesis. Journal of Neuroendocrinology 18, 629-631.
42. Millan MJ, Brocco M, Gobert A, Dekeyne A (2005). Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 177, 448-458.
43. Millan MJ, Gobert A, Lejeune F, Dekeyne A, et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 306, 954-964.
44. Montkowski A, Barden N, Wotjak C, Stec I, et al. (1995). Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. Journal of Neuroendocrinology 7, 841-845.
45. Morley-Fletcher S, Mairesse J, Mocaer E, Darnaudéry M, et al. (2003). Chronic treatment with agomelatine increases hippocampal cell proliferation in prenatally stressed rats. Program No.506.20 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience 2003. Online.
46. Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. International Journal of Neuropsychopharmacology 10, 661-673.
47. Paizanis E, Kelai S, Renoir T, Hamon M, Lanfumey L (2007). Life-long hippocampal neurogenesis: environmental, pharmacological and neurochemical modulations. Neurochemical Research 32, 1762-1771.
48. Papp M, Gruca P, Boyer PA, Mocaer E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28, 694-703.
49. Pariante CM, Kim RB, Makoff A, Kerwin RW (2003). Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. British Journal of Pharmacology 139, 1111-1118.
50. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry 49, 391-404.
51. Pepin MC, Pothier F, Barden N (1992). Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 355, 725-728.
52. Rajkowska G (2000). Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry 48, 766-777.
53. Rao MS, Shetty AK (2004). Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. European Journal of Neuroscience 19, 234-246.
54. Reif A, Fritzen S, Finger M, Strobel A, et al. (2006). Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Molecular Psychiatry 11, 514-522.
55. Renoir T, Paizanis E, El Yacoubi M, Saurini F, et al. (2008). Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. International Journal of Neuropsychopharmacology 11, 1149-1162.
56. Rousse I, Beaulieu S, Rowe W, Meaney MJ, et al. (1997). Spatial memory in transgenic mice with impaired glucocorticoid receptor function. Neuroreport 8, 841-845.
57. Saarelainen T, Hendolin P, Lucas G, Koponen E, et al. (2003). Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. Journal of Neuroscience 23, 349-357.
58. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E (2005). Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. Journal of Neuroscience 25, 1089-1094.
59. Santarelli L, Saxe M, Gross C, Surget A, et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809.
60. Seckl JR, Fink G (1992). Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 55, 621-626.
61. Sheline YI (2000). 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biological Psychiatry 48, 791-800.
62. Thierry B, Steru L, Chermat R, Simon P (1984). Searching-waiting strategy: a candidate for an evolutionary model of depression? Behavioral and Neural Biology 41, 180-189.
63. Tsankova NM, Berton O, Renthal W, Kumar A, et al. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience 9, 519-525.
64. Vinet J, Carra S, Blom JM, Brunello N, et al. (2004). Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology 47, 1062-1069.
65. West MJ, Gundersen HJ (1990). Unbiased stereological estimation of the number of neurons in the human hippocampus. Journal of Comparative Neurology 296, 1-22.
66. Zhou Q, Homma KJ, Poo MM (2004). Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 44, 749-757.